{
    "clinical_study": {
        "@rank": "40158", 
        "arm_group": {
            "arm_group_label": "Treatment (orteronel)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well orteronel works in treating patients with metastatic\n      hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking\n      some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adenocarcinoma of the Prostate", 
            "Hormone-resistant Prostate Cancer", 
            "Recurrent Prostate Cancer", 
            "Stage IV Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess the relationship between circulating tumor cell (CTC)-based androgen receptor\n      (AR) expression level and >=-50% prostate-specific antigen (PSA) decline following 12 weeks\n      of therapy with TAK-700 (orteronel).\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess changes in PSA and CTC levels and time to PSA progression (best response,\n      decline at 12 weeks as continuous variable, etc.) with or without prior docetaxel-based\n      treatment.\n\n      II. To assess measurable disease response and time to radiographic disease progression for\n      castration-resistant prostate cancer (CRPC) with or without prior docetaxel-based treatment.\n\n      III. To explore relationships between endocrine and clinical responses.\n\n      IV. To confirm the safety of TAK-700 administered without prednisone in patients with\n      metastatic CRPC.\n\n      OUTLINE: Patients receive orteronel orally (PO) twice daily (BID) on days 1-28. Courses\n      repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed adenocarcinoma of the prostate\n\n          -  Voluntary written informed consent before performance of any study-related procedure\n             not part of normal medical care, with the understanding that consent may be withdrawn\n             by the subject at any time without prejudice to future medical care\n\n          -  Patients, even if surgically sterilized (i.e., status post vasectomy), who agree to\n             practice effective barrier contraception during the entire study treatment period and\n             for 4 months after the last dose of study drug, or\n\n          -  Agree to completely abstain from intercourse\n\n          -  Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =<\n             2.5 x the upper limit of normal (ULN)\n\n          -  Total bilirubin =< 1.5 x ULN\n\n          -  Estimated creatinine clearance using the Cockcroft-Gault formula must be > 40\n             mL/minute\n\n          -  Absolute neutrophil count (ANC) >= 1500/uL\n\n          -  Platelet count >= 100,000/uL\n\n          -  Testosterone < 50 ng/dL\n\n          -  Screening calculated ejection fraction of >= 50% by multiple gated acquisition (MUGA)\n             scan or echocardiogram; metastatic progression on primary androgen-deprivation\n             therapy (medical or surgical castration)\n\n          -  Progression requiring a change in oncologic therapy defined by any of the following:\n\n               -  Radiographic progression: appearance or increase in measurable lesions on\n                  cross-sectional imaging or appearance of one or more new lesions on bone scan\n                  * Rising PSA (>= 2 ng/ml) which has risen on two occasions >= 1 week apart\n\n               -  Clinical progression evidenced by increased pain or other cancer-related\n                  symptoms\n\n          -  Patients should have recovered from prior oncologic therapies to a Common Terminology\n             Criteria (CTC) grade =< 1 except stable neuropathy or alopecia at National Cancer\n             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2; if\n             rapid clinical progression is documented by imaging, changes in PSA, or symptoms,\n             then study treatment can begin >= 2 weeks from prior therapy; otherwise, the\n             following time periods between prior anti-cancer therapies and study treatment day 1\n             will apply:\n\n               -  >= 3 weeks for prior cytotoxic therapies\n\n               -  >= 4 weeks for flutamide or nilutamide\n\n               -  >= 6 weeks for bicalutamide\n\n               -  >= 6 weeks since bone targeted radiopharmaceutical (e.g. samarium-153,\n                  radium-223)\n\n          -  Gonadotropin-releasing hormone (GnRH) agonists (leuprolide acetate, goserelin, etc.)\n             or antagonists (degarelix, etc.) should be continued in patients without\n             surgically-induced castrate androgen levels\n\n          -  For chemotherapy na\u00efve castration-resistant prostate cancer who are moderately\n             symptomatic or who have hepatic metastasis: subjects must not be a candidate for\n             docetaxel-based chemotherapy.\n\n        Exclusion Criteria:\n\n          -  History of myocardial infarction, unstable symptomatic ischemic heart disease,\n             ongoing arrhythmias of grade > 2 (NCI CTCAE, version 4), thromboembolic events (e.g.,\n             deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or\n             any other cardiac condition (e.g. pericardial effusion, restrictive cardiomyopathy)\n             within 6 months prior to first dose of study drug; chronic stable atrial fibrillation\n             on stable anticoagulant therapy is allowed\n\n          -  New York Heart Association class III or IV heart failure\n\n          -  Electrocardiogram (ECG) abnormalities of:\n\n               -  Q-wave infarction, unless identified 6 or more months prior to screening\n\n               -  Corrected QT (QTc) interval > 460 msec\n\n          -  Patient has received other investigational drugs within 28 days before enrollment\n\n          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the\n             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of\n             the skin, an in situ malignancy\n\n          -  Known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients\n\n          -  Uncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] of\n             greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no\n             more than 60 minutes apart during the screening visit); Note: patients may be\n             rescreened after adjustment of antihypertensive medications\n\n          -  Known active chronic hepatitis B or C, life-threatening illness unrelated to cancer,\n             or any serious medical or psychiatric illness that could, in the investigator's\n             opinion, potentially interfere with participation in this study\n\n          -  Likely inability to comply with the protocol or cooperate fully with the investigator\n             and site personnel\n\n          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI\n             absorption or tolerance of TAK-700, including difficulty swallowing tablets\n\n          -  Prior treatment with >= 3 lines of cytotoxic chemotherapy for metastatic prostate\n             cancer\n\n          -  Prior treatment with TAK-700"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866423", 
            "org_study_id": "4P-13-1", 
            "secondary_id": [
                "NCI-2013-01013", 
                "IISR-2012-M000668", 
                "P30CA014089"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (orteronel)", 
                "description": "Given PO", 
                "intervention_name": "orteronel", 
                "intervention_type": "Drug", 
                "other_name": "TAK-700"
            }, 
            {
                "arm_group_label": "Treatment (orteronel)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "kristy.massopust@med.usc.edu", 
                "last_name": "Kristy Massopust", 
                "phone": "323-865-0843"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033"
                }, 
                "name": "USC Norris Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Mitchell E. Gross", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Trial of TAK-700 (Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer", 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Mitchell Gross", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The two-sample t-test will be used. Once association between AR protein expression levels and response is established, graphical methods such as receiver-operator curves (ROC) or more quantitative methods such as the maximal chi-square method to determine whether there might be a cut-point with either great sensitivity or great specificity (or both) for identifying a cohort with either a high or low likelihood of PSA response.", 
                "measure": "AR protein expression levels in CTCs", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "Standard descriptive methods will be used to summarize PSA. Values will be tabulated as outlined in the Prostate Cancer Working Group 2 (PCWG2) criteria and presented as Kaplan-Meier survival curves, as appropriate.", 
                "measure": "PSA response, defined as occurrence of PSA decline to greater than or equal to 50% from baseline", 
                "safety_issue": "No", 
                "time_frame": "At 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.", 
                "measure": "Best PSA response", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "description": "Values will be tabulated as outlined in the PCWG2 criteria and presented as Kaplan-Meier survival curves, as appropriate.", 
                "measure": "Absolute change in PSA", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 24 weeks"
            }, 
            {
                "description": "Response will be tabulated descriptively with 95% confidence intervals (CIs) and Kaplan-Meier survival curves, as appropriate.", 
                "measure": "Overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and PCWG2 criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Response will be tabulated descriptively with 95% CIs and Kaplan-Meier survival curves, as appropriate.", 
                "measure": "Duration of response using RECIST version 1.1 and PCWG2 criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "All toxicities observed will be summarized with tables according to system, specific toxicity, grade, attribution, and time of onset.", 
                "measure": "Incidence of adverse events by NCI CTCAE version 4", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "source": "University of Southern California", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Millennium Pharmaceuticals, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Southern California", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}